Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback